



## **Alzinova AB announces subscription commitments corresponding to 26.6 percent of outstanding warrants of series TO3**

**Alzinova AB ("Alzinova" or the "Company") announces today that the Company has received subscription commitments from larger holders of warrants of series TO3 (the "Warrants") including members of the Company's Board of Directors and management group as well as founders of the Company.**

The subscription commitments received from the holders involves 3,454,992 Warrants, corresponding to 26.6 percent of the outstanding number of Warrants. In total, the subscription commitments correspond to an issue volume of approximately SEK 7.5 million and a majority of the subscription commitments are entered into by the Company's Board of Directors and management group. Parts of the subscription commitments have been entered into by founders of the Company. The subscription commitments have been agreed in writing and no compensation is to be paid for the commitments. The subscription commitments are not secured through bank guarantees, restricted funds, pledged assets or similar arrangements.

The exercise period for the Warrants began on April 11, 2023 and continues until April 25, 2023.

Complete terms and conditions for the Warrants are available on the Company's campaign page: [www.to3.alzinova.com](http://www.to3.alzinova.com).

### **Advisers**

Mangold Fondkommission AB is the financial adviser, Fredersen Advokatbyrå AB is the legal adviser and Shark Communication is the communication adviser to the Company in connection with the exercise of the Warrants.

### **For questions regarding the Warrants, please contact:**

Mangold Fondkommission AB  
E-mail: [emissioner@mangold.se](mailto:emissioner@mangold.se)

### **For more information, please contact:**

Kristina Torfgård, CEO  
Tel. +46 708 46 79 75  
E-mail: [kristina.torfgard@alzinova.com](mailto:kristina.torfgard@alzinova.com)

*Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.*



### **About Alzinova**

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A $\beta$ CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: [www.alzinova.com](http://www.alzinova.com)

### **Attachments**

**Alzinova AB announces subscription commitments corresponding to 26.6 percent of outstanding warrants of series TO3**